What benefits does Tralokinumab offer for IL13 research applications?

Tralokinumab is a recombinant human monoclonal antibody that has been validated in ELISA, flow cytometry, and immunoprecipitation. Its precise recombinant design ensures high specificity for IL13, contributing to reliable and consistent performance in a range of research applications.

How do its quality controls and purity measures improve assay reliability?

With confirmed purity over 95% by RP-HPLC and SDS-PAGE, Tralokinumab minimizes background interference in experiments. The detailed quality control measures and recombinant production in CHO cells guarantee that the antibody consistently performs well in functional assays, ELISA, and flow cytometry, ensuring robust research data.

Anti-Human IL13 Recombinant Antibody (Tralokinumab)

CAT#: TAB-218

Recombinant monoclonal antibody to IL13. Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13, and is designed for the treatment of asthma and inflammatory diseases.

Published Data Tested Data Gene Expression

Figure 1 Tralokinumab prevents IL-13 from interacting with both (a) IL-13Rα1 and (b) IL-13Rα2.

Data are shown as mean % DeltaF (standard error of the mean) from two independent experiments each performed in duplicate.

Popovic, B., Breed, J., Rees, D. G., Gardener, M. J., Vinall, L. M. K., Kemp, B., ... & Colice, G. (2017). Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. Journal of molecular biology, 429(2), 208-219.

Figure 2 Overall structure of the tralokinumab:IL-13 complex.

Heavy chain (VH) is coloured in dark blue, light chain (VL) is coloured in light blue, and IL-13 is shown in purple. Helices A–D of IL-13 are also labelled.

Figure 3 Neutralization of fibroblast-derived IL-13 inhibits lung fibrosis in an established fibroblast-driven disease setting in humanized SCID mice.

(A–C)Isolated IPF ﬁbroblasts (n= 5) or normal lung tissue ﬁbroblasts (n= 5) were injected intravenously to SCID mice, and animals were killed at speciﬁcsubsequent time points. Whole lung mRNA expression was measured by quantitative RT-PCR for il-13 (A), il113ra1(B), and il-13ra2(C) and normalized tolung mRNA expression levels from mice that had received normal lung tissue-derived ﬁbroblasts. (D–N) Thirty-ﬁve days after IPF ﬁbroblast engraftment,mice were randomized and treated with PBS control, control IgG4, or tralokinumab (anti–IL-13 mAb) every other day until analysis at Day 63.Representative mouse lung sections stained with Masson's trichrome to depict the degree of ﬁbrosis at Day 63 from SCID/IPF mice treated with PBScontrol (D), CAT251 IgG4isotype control (E), and tralokinumab anti–IL-13 antibody (F). Fibrosis was quantitated in all animals using a modiﬁedAshcroft score of histological sections (G). Tralokinumab attenuated serum CC16 levels as measured by ELISA (H) and BAL caspase 3 activity (I). Data aremean 6SEM (n= 5). (J–M) Representative immunohistochemistry localizing IL-13Ra2 expression in the lungs of control SCID mice that have notreceived IPF ﬁbroblast (J) or SCID/IPF mice treated with PBS control (K), isotype control (L), or tralokinumab (M). Original magniﬁcation: top panels,340;bottom panels,3200. *p<0.05, **p<0.01, and ***p<0.005.

Murray, L. A., Zhang, H., Oak, S. R., Coelho, A. L., Herath, A., Flaherty, K. R., ... & Sleeman, M. A. (2014). Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. American journal of respiratory cell and molecular biology, 50(5), 985-994.

Figure 4 Enhanced epithelial markers in the lungs of SCID/IPF mice treated with tralokinumab.

Whole lung mRNA expression from mice treated withisotype control or tralokinumab (anti–IL-13) was measured using quantitative RT-PCR. Levels of vimentin (A), TGF-b1(B), surfactant protein a (C),surfactant protein b (D), surfactant protein c (E), surfactant protein d (F), and e-cadherin (G) were quantitated and normalized to lung mRNA expressionlevels from SCID/IPF mice that had received PBS control only. Data are mean 6SEM (n= 5). *p<0.05.

❮

❯

ELISA

Figure 1 Anti-Human IL13 Antibody (Tralokinumab) (TAB-218) in ELISA

ELISA analysis of TAB-218 was performed by coating with Recombinant Human IL3.

❮

❯

Subcellular Location Figure 1 IF staining of human cell line U-2 OS

Immunofluorescent staining of human cell line U-2 OS shows localization to plasma membrane & cytosol.

* Image credit: Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/42421/if_selected.jpg

Subcellular Location Figure 2 IF staining of human cell line A-431

Immunofluorescent staining of human cell line A-431 shows localization to plasma membrane & cytosol.

* Image credit: Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/42421/475_E8_1_blue_red_green.jpg

Subcellular Location Figure 3 IF staining of human cell line U-251 MG

Immunofluorescent staining of human cell line U-251 MG shows localization to plasma membrane & cytosol.

* Image credit: Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/42421/477_E8_1_blue_red_green.jpg

RNA Expression Figure 4 RNA cell line category: Cell line enriched (HDLM-2)

Cell lines ordered by descending RNA expression order.

* Image credit: Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000169194-IL13

❮

❯

Specifications

Immunogen
The details of the immunogen for this antibody are not available.

Host Species
Human

Derivation
Human

Type
IgG4 - lambda

Specificity
Tested positive against native human antigen.

Species Reactivity
Human

Applications
ELISA, FC, IP, FuncS, IF, Neut, ICC

CAS
1044515-88-9

Generic Name
Tralokinumab

MW
143.87 kDa

Related Disease
Asthma, severe

Product Property

Purity
>95.0%. Determined by analysis by RP-HPLC & analysis by SDS-PAGE.

Storage
At -20°C for one year.

Applications

Application Notes
The IL13 antibody has been reported in applications of Inhib, X-ray structure, IHC, RT-PCR.

Target

Alternative Names
Tralokinumab;1044515-88-9;CAT-354;BAK502G9;IL13;interleukin 13;interleukin-13;allergic rhinitis;ALRH;BHR1;Bronchial hyperresponsiveness 1 (bronchial asthma);IL 13;MGC116786;MGC116788;MGC116789;P600;Bronchial hyperresponsiveness-1 (bronchial asthma);IL-13;

Gene ID
3596

UniProt ID
P35225

REVIEWS AND Q&AS CITATIONS RESOURCES DOWNLOADS RELATED PRODUCTS

Inquiry

Navs

Customer Review

There are currently no Customer reviews or questions for TAB-218. Click the button above to contact us or submit your feedback about this product.

Breast cancer biomarkers at key points during disease progression

Reliable IL13 Tool

Tralokinumab has proved to be a reliable tool in my experiments focused on IL13 detection using ELISA and immunoprecipitation. The recombinant human monoclonal format ensures high consistency and the detailed data on purity has been invaluable in optimizing my assay conditions.

Consistent and Clear

I appreciate the clarity provided by the application notes for this IL13 antibody. It worked well across various platforms including flow cytometry and functional assays. The high purity and robust recombinant design have reduced variability, providing consistent and reliable data for my research projects.

Q&As

What benefits does Tralokinumab offer for IL13 research applications?

A: Tralokinumab is a recombinant human monoclonal antibody that has been validated in ELISA, flow cytometry, and immunoprecipitation. Its precise recombinant design ensures high specificity for IL13, contributing to reliable and consistent performance in a range of research applications.
How do its quality controls and purity measures improve assay reliability?

A: With confirmed purity over 95% by RP-HPLC and SDS-PAGE, Tralokinumab minimizes background interference in experiments. The detailed quality control measures and recombinant production in CHO cells guarantee that the antibody consistently performs well in functional assays, ELISA, and flow cytometry, ensuring robust research data.

View the frequently asked questions answered by Creative Biolabs Support.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-218, RRID: AB_3111879)

Copy citation

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Biosimilar Overview

Please refer to Tralokinumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Tralokinumab.

Related Diseases

Asthma

Inflammatory Bowel Diseases

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

Datasheet - TAB-218.pdf

MSDS

MSDS - TAB-218.pdf

COA

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Lot Number:

Protocol & Troubleshooting

Immunofluorescence (IF)

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "Tralokinumab"

Afuco™ Anti-IL13 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-218)
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL13. It is a human monoclonal antibody which targets the cytokine interleukin 13, and is designed for the treatment of asthma and inflammatory diseases.

DrugMonitor™ Anti-Tralokinumab Antibody (VS-1224-YC1235)
Tralokinumab is a monoclonal antibody targeting interleukin-13, used in the treatment of moderate-to-severe atopic dermatitis in patients requiring systemic therapy. The DrugMonitor™ Anti-Tralokinumab Antibody (VS-1224-YC1235) is an anti-drug antibody (ADA) against Tralokinumab. This drug-based antibody is raised in mice immunized with the Tralokinumab. The anti-Tralokinumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Tralokinumab in samples.

See other products for "IL13"

Select a product category from the dropdown menu below to view related products.

CAT	Product Name	Application	Type
MOB-1287z	Mouse Anti-IL13 Recombinant Antibody (clone 39B4)	WB, IP, IF, ELISA	Mouse IgG1, κ

CAT	Product Name	Application	Type
TAB-H05	Anti-Human IL13 Recombinant Antibody (Anrukinzumab)	ELISA, Inhib	IgG1

CAT	Product Name	Application	Type
TAB-219	Anti-Human IL13 Recombinant Antibody (TAB-219)	ELISA, Neut, IF, IP, FC, FuncS	IgG4 - kappa

CAT	Product Name	Application	Type
TAB-395CL	Human Anti-IL13 Recombinant Antibody (TAB-395CL)	FuncS	Human IgG

CAT	Product Name	Application	Type
PABL-232	Human Anti-IL13 Recombinant Antibody (clone M1295)	WB, IHC, FuncS	Human IgG

CAT	Product Name	Application	Type
PSBL-232	Human Anti-IL13 Recombinant Antibody (clone M1295); scFv Fragment	WB, IHC, FuncS	Human scFv

CAT	Product Name	Application	Type
PFBL-232	Human Anti-IL13 Recombinant Antibody (clone M1295); Fab Fragment	WB, IHC, FuncS	Human Fab

CAT	Product Name	Application	Type
PABL-603	Human Anti-IL13 Recombinant Antibody (clone C836)	Neut	Chimeric (mouse/human) IgG

CAT	Product Name	Application	Type
PABL-605	Human Anti-IL13 Recombinant Antibody (clone H2L6)	ELISA	Humanized IgG

CAT	Product Name	Application	Type
PABL-606	Human Anti-IL13 Recombinant Antibody (clone X836)	WB, ELISA, FuncS	Chimeric (mouse/human) IgG

CAT	Product Name	Application	Type
PFBL-598	Human Anti-IL13 Recombinant Antibody (clone C836); Fab Fragment	Neut	Chimeric (mouse/human) Fab

CAT	Product Name	Application	Type
PFBL-600	Human Anti-IL13 Recombinant Antibody (clone H2L6); Fab Fragment	ELISA	Humanized Fab

CAT	Product Name	Application	Type
PFBL-601	Human Anti-IL13 Recombinant Antibody (clone X836); Fab Fragment	WB, ELISA, FuncS	Chimeric (mouse/human) Fab

CAT	Product Name	Application	Type
PFBW-170	Human Anti-IL13 Recombinant Antibody (clone CNTO607); Fab Fragment	ELISA, WB, Neut	Human Fab

CAT	Product Name	Application	Type
PSBL-598	Mouse Anti-IL13 Recombinant Antibody (clone C836); scFv Fragment	Neut	Mouse scFv

CAT	Product Name	Application	Type
PSBL-600	Human Anti-IL13 Recombinant Antibody (clone H2L6); scFv Fragment	ELISA	Humanized scFv

CAT	Product Name	Application	Type
PSBL-601	Mouse Anti-IL13 Recombinant Antibody (clone X836); scFv Fragment	WB, ELISA, FuncS	Mouse scFv

CAT	Product Name	Application	Type
PSBW-170	Human Anti-IL13 Recombinant Antibody (clone CNTO607); scFv Fragment	ELISA, WB, Neut	Human scFv

CAT	Product Name	Application	Type
TAB-022ZJ	Anti-Human IL-13 Recombinant Antibody (C836)	ELISA

CAT	Product Name	Application	Type
TAB-023ZJ	Mouse Anti-IL13 Recombinant Antibody (TAB-023ZJ)	ELISA, Block	Mouse IgG

CAT	Product Name	Application	Type
TAB-043ZJ	Anti-Human IL-13 Recombinant Antibody (Lc6Hc2)	ELISA	Humanized antibody

CAT	Product Name	Application	Type
TAB-044ZJ	Human Anti-IL13 Recombinant Antibody (TAB-044ZJ)	ELISA, Neut	Humanized IgG

CAT	Product Name	Application	Type
TAB-068ZJ	Anti-Human IL-13 Recombinant Antibody (TAB-068ZJ)	WB, ELISA, Neut	Human antibody

CAT	Product Name	Application	Type
TAB-069ZJ	Human Anti-IL13 Recombinant Antibody (TAB-069ZJ)	ELISA, Neut, FC	Human IgG

CAT	Product Name	Application	Type
TAB-070ZJ	Human Anti-IL13 Recombinant Antibody (TAB-070ZJ)	ELISA, Neut, FC	Human IgG

CAT	Product Name	Application	Type
TAB-094ZJ	Anti-Human IL-13 Recombinant Antibody (167)	ELISA	Chimeric antibody (mouse/human)

CAT	Product Name	Application	Type
TAB-022ZJ-S(P)	Anti-Human IL-13 Recombinant Antibody scFv Fragment (C836)	ELISA

CAT	Product Name	Application	Type
TAB-023ZJ-S(P)	Mouse Anti-IL13 Recombinant Antibody; scFv Fragment (TAB-023ZJ-S(P))	ELISA, Block	Mouse scFv

CAT	Product Name	Application	Type
TAB-067ZJ-S(P)	Anti-Human IL-13 Recombinant Antibody scFv Fragment (CNTO 607)	ELISA, Inhib	Human antibody

CAT	Product Name	Application	Type
TAB-068ZJ-S(P)	Anti-Human IL-13 Recombinant Antibody scFv Fragment (TAB-068ZJ-S(P))	ELISA, Neut	Human antibody

CAT	Product Name	Application	Type
TAB-094ZJ-S(P)	Anti-Human IL-13 Recombinant Antibody scFv Fragment (167)	ELISA	Chimeric antibody (mouse/human)

CAT	Product Name	Application	Type
TAB-022ZJ-F(E)	Anti-Human IL-13 Recombinant Antibody Fab Fragment (C836)	ELISA

CAT	Product Name	Application	Type
TAB-094ZJ-F(E)	Anti-Human IL-13 Recombinant Antibody Fab Fragment (167)	ELISA	Chimeric antibody (mouse/human)

CAT	Product Name	Application	Type
NEUT-1171CQ	Mouse Anti-IL13 Recombinant Antibody (clone B-B13)	ELISA, ELISPOT, Neut	Mouse IgG1

CAT	Product Name	Application	Type
NEUT-1172CQ	Mouse Anti-IL13 Recombinant Antibody (clone 10X28)	Neut, WB	Mouse IgG1

CAT	Product Name	Application	Type
NEUT-1173CQ	Mouse Anti-IL13 Recombinant Antibody (NEUT-1173CQ)	Neut	Mouse IgG2b

CAT	Product Name	Application	Type
NEUT-1174CQ	Mouse Anti-IL13 Recombinant Antibody (clone 32116.11)	ELISA, Neut, WB	Mouse IgG1

CAT	Product Name	Application	Type
NEUT-1175CQ	Rat Anti-IL13 Recombinant Antibody (clone 5A2)	Neut	Rat IgG1

CAT	Product Name	Application	Type
MOR-1790	Rabbit Anti-IL13 Recombinant Antibody (clone DS1790AB)	WB, ICC, FC, IP	Rabbit IgG

CAT	Product Name	Application	Type
MOR-4610	Rabbit Anti-IL13 Recombinant Antibody (clone TH123DS)	WB	Rabbit IgG

CAT	Product Name	Application	Type
AFC-TAB-H05	Afuco™ Anti-IL13 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-H05)	FC, IP, ELISA, Neut, FuncS, IF	ADCC enhanced antibody

CAT	Product Name	Application	Type
AFC-TAB-017ML	Afuco™ Anti-IL13 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-017ML)	ELISA, IHC, FC, IP, IF, Inhib	ADCC enhanced antibody

CAT	Product Name	Application	Type
AFC-TAB-219	Afuco™ Anti-IL13 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-219)	ELISA, Neut, IF, IP, FC, FuncS	ADCC enhanced antibody

CAT	Product Name	Application	Type
AFC-TAB-218	Afuco™ Anti-IL13 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-218)	ELISA, FC, IP, FuncS, IF, Neut	ADCC enhanced antibody

CAT	Product Name	Application	Type
VS-0225-XY129	CytoStream™ Rat Anti-IL13 Recombinant Antibody (clone JES10-5A2)	ELISA, FC, Neut, IHC, WB	Rat IgG1

CAT	Product Name	Application	Type
VS-0425-FY124	Human Anti-IL13 (clone IMA-638) scFv-Fc Chimera	ELISA, FC	Human IgG1, scFv-Fc

CAT	Product Name	Application	Type
VS-0525-XY3484	Anti-IL13 Immunohistochemistry Kit	IHC

CAT	Product Name	Application	Type
VS-0525-YC216	Recombinant Anti-IL13 Biparatopic Antibody, Tandem scFv (Anrukinzumab x Clone IMA-026)	ELISA	Tandem scFv

CAT	Product Name	Application	Type
VS-0625-YC165	Recombinant Anti-IL13 Eliminating Antibody, pH-Sensitive (VS-0625-YC165)	Antigen-Sweeping In Vivo.	Human IgG4 lambda

CAT	Product Name	Application	Type
VS-0825-YC173	SmartAb™ Recombinant Anti-IL13 pH-dependent Antibody (Clone Tralokinumab)	ELISA, FC, IP IF, Neut, ICC	Human IgG4 lambda

Specific Inquiry

Size:

Conjugation:

Endotoxin:

Purity:

Formats:

Isotype Switching:

Fc Engineering:

Modalities:

Add to compare

Request
Custom Production

See Our Custom Production in Action

Figure 1 Anti-HBV Recombinant Antibody (TAB-147) in SDS-PAGE

Download the full case study

Popular Products

Figure 3 Anti-CD40 Antibody (TAB-039) in Dot Blot

Anti-Human CD4 Recombinant Antibody (Zanolimumab) (CAT# TAB-039)
Application: Neut, ELISA, IF, IP, FuncS, FC, IHC

Figure 2 Anti-Human DR5 Recombinant Antibody (TAB-203) in WB

Human Anti-TNFRSF10B Recombinant Antibody (TAB-203) (CAT# TAB-203)
Application: ELISA, IP, FC, FuncS, Neut, IF, ICC

Figure 3 Anti-Human TNF beta Antibody (TAB-071) in DB

Anti-Human TNF beta Recombinant Antibody (TAB-071) (CAT# TAB-071)
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC

Figure 3 Anti-Human Frizzled receptor Antibody (TAB-880) in ELISA

Anti-Human Frizzled receptor Recombinant Antibody (Vantictumab) (CAT# TAB-880)
Application: Inhib, Cyt

Figure 3 Anti-Human FLT3 Therapeutic Antibody (TAB-291CL) in ELISA

Anti-Human FLT3 Recombinant Antibody (IMC-EB10) (CAT# TAB-291CL)
Application: WB, IHC, FC, Cyt, ELISA

Figure 2 Anti-Human Laminin-332 Recombinant Antibody (TAB-481CL) in HPLC

Anti-Human Laminin-332 Recombinant Antibody (CAT# TAB-481CL)
Application:

Figure 3 Anti-Human VEGF Antibody Fab Fragment (TP-104CL) in DB

Human Anti-Human VEGF Recombinant Antibody; Fab Fragment (TP-104CL) (CAT# TP-104CL)
Application:

Figure 3 Human Anti-HIV-1 gp41 Recombinant Antibody (clone 4E10) (PABL-192) in Dot Blot

Human Anti-HIV-1 gp41 Recombinant Antibody (clone 4E10) (CAT# PABL-192)
Application: WB, Neut, FuncS

Figure 2 Anti-PF4 Recombinant Antibody (PABL-299) in HPLC

Mouse Anti-PF4 Recombinant Antibody (clone KKO) (CAT# PABL-299)
Application: ELISA, FuncS

Figure 2 Mouse Anti-DOTA Recombinant Antibody (PABW-133) in HPLC

Mouse Anti-DOTA Recombinant Antibody (clone 2D12.5) (CAT# PABW-133)
Application: ELISA

Figure 1 Mouse Anti-α4β7 Recombinant Antibody (PABL-746) in ELISA

Mouse Anti-α4β7 Recombinant Antibody (PABL-746) (CAT# PABL-746)
Application: FC

Figure 2 Anti-Human DEspR Recombinant Antibody (TAB-190MZ) in HPLC

Anti-Human DEspR Recombinant Antibody (TAB-190MZ) (CAT# TAB-190MZ)
Application: FC, FuncS, Inhib

Figure 5 Anti-Human RNF43 Antibody Fab Fragment (TAB-328CT-F(E)) in DB

Humanized Anti-RNF43 Recombinant Antibody; Fab Fragment (TAB-328CT-F(E)) (CAT# TAB-328CT-F(E))
Application: WB, ELISA, FC, IHC, IP

Figure 5 Human Anti-TREM2 Recombinant Antibody (TAB-168CQ) in ELISA

Human Anti-TREM2 Recombinant Antibody (TAB-168CQ) (CAT# TAB-168CQ)
Application: ELISA, FC, WB, FuncS

Figure 2 Anti-CD5 Antibody (53-7.3) Fab Fragment (NEUT-392CQ-Fab) in ELISA

Rat Anti-CD5 Recombinant Antibody (clone 53-7.3) (CAT# NEUT-392CQ)
Application: FC, IHC-Fr, IP, ELISA, Block

Figure 3 Anti-Human FCGRT Antibody (TAB-450CQ) in ELISA

Anti-Human FCGRT Recombinant Antibody (TAB-450CQ) (CAT# TAB-450CQ)
Application: ELISA, IHC, FC, IP, IF, FuncS

Figure 2 Human Anti-GPC3 Recombinant Antibody (HPAB-0563-CN) in HPLC

Human Anti-GPC3 Recombinant Antibody (clone hGC33) (CAT# HPAB-0563-CN)
Application: ELISA

Figure 1 Human Anti-ROR1 Recombinant Antibody (HPAB-0181-LSX) in SDS-PAGE

Human Anti-ROR1 Recombinant Antibody (HPAB-0181-LSX) (CAT# HPAB-0181-LSX)
Application: ELISA, FC, IF, IHC, WB

Figure 5 Mouse Anti-FCRL5 Recombinant Antibody (MOB-056CQ) in DB

Mouse Anti-FCRL5 Recombinant Antibody (MOB-056CQ) (CAT# MOB-056CQ)
Application: ELISA, FC, FuncS

Figure 2 Human Anti-HLA-DR4 Recombinant Antibody (HPAB-0827-FY) in HPLC

Human Anti-HLA-DR4/GAD-555-567 Recombinant Antibody (clone G1H12) (CAT# HPAB-0827-FY)
Application: FC

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.